(Q42536982)

1 November 2017

title

Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study (English)

1 reference

1 November 2017

main subject

phase II clinical trial

0 references

metastatic breast cancer

1 reference

1 reference

Geyer CE Jr

1

1 reference

1 November 2017

Green SJ

2

1 reference

1 November 2017

Moinpour CM

3

1 reference

1 November 2017

O'Sullivan J

4

1 reference

1 November 2017

Goodwin DK

5

1 reference

1 November 2017

Canfield VA

6

1 reference

1 November 2017

Meyers FJ

7

1 reference

1 November 2017

Osborne CK

8

1 reference

1 November 2017

Martino S

9

1 reference

1 November 2017

language of work or name

English

0 references

publication date

1 September 1998

1 reference

Breast Cancer Research and Treatment

1 November 2017

published in

1 reference

1 November 2017

volume

51

1 reference

1 November 2017

issue

2

1 reference

1 November 2017

page(s)

169-181

1 reference

Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Adjustment of women and their husbands to recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Coefficient alpha and the internal structure of tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

Quality of life end points in cancer clinical trials: review and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

A randomized clinical trial of home nursing care for lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

7 January 2021

The measurement of symptom distress

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

7 January 2021

Depressive phenomena, physical symptom distress, and functional status among women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

7 January 2021

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

7 January 2021

Assessment of quality-of-life outcomes

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006094403153

7 January 2021

Identifiers

DOI

10.1023/A:1006094403153

1 reference

Dimensions Publication ID

1 November 2017

1038540512

0 references

1 reference